Immunization of cattle against rabies using inactivated cell culture vaccines.

Acta Vet Scand

National Veterinary and Food Research Institute, Department of Production and Vaccines, Helsinki, Finland.

Published: October 1995

Twenty-one heads of cattle were vaccinated with Madibovin, 31 with Rabdomun and 127 with Rabisin on 4 different farms. Rabies neutralizing antibody titre (> or = 0.5 IU/ml) was detected in 80% of 163 animals tested about 1 month and in 42% of 133 animals tested about 1 year after primary vaccination. On 3 of the farms 86 animals received booster vaccination about 1 year after primary vaccination. All these animals had antibody titre (> or = 0.5 IU/ml) about 1 month after booster and antibody levels were higher than after the primary vaccination. Rabies antibody titres (> or = 0.5 IU/ml) were detected in 96% of 50 animals tested 1 year after the booster. No significant differences (p > 0.05) in antibody levels were detected between animals vaccinated with Madibovin or Rabisin (farm C) respectively with Rabisin or Rabdomun (farm D) at any collection time. Responses to rabies vaccines varied considerably between the farms. After primary vaccination of the animals on 2 farms with the same batch of Rabisin, the antibody levels clearly differed (p < 0.0001) between the farms. Our results indicate that booster is always necessary after primary vaccination to ensure that all animals are protected.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101428PMC
http://dx.doi.org/10.1186/BF03548310DOI Listing

Publication Analysis

Top Keywords

primary vaccination
20
animals tested
12
antibody levels
12
vaccinated madibovin
8
antibody titre
8
titre iu/ml
8
iu/ml detected
8
animals
8
tested year
8
year primary
8

Similar Publications

Background: Risk of herpes zoster (HZ) infection increases with age and immunosuppression. We estimated the impact of HZ and post-herpetic neuralgia (PHN) on direct costs and health care resource utilization (HCRU) in patients ≥50 years, including those with comorbidities, as limited information exists in Italy.

Methods: This retrospective analysis used reimbursement data from local health authorities in Italy (January 2009-June 2022).

View Article and Find Full Text PDF

Metarhizium anisopliae: current status and future in hard ticks control in Asia.

Trop Biomed

December 2024

Mycology and Pathology Branch, Forest Health and Conservation Programme, Forest Biodiversity Division, Forest Research Institute Malaysia, 52109 Kepong, Selangor, Malaysia.

Ticks exert a significant economic impact on the livestock industry, particularly in Asian regions. Presently, chemical acaricides constitute the primary method employed to combat tick infestations in livestock, but their use carries adverse environmental consequences. Overreliance on acaricides has contaminated milk and meat products with chemical residues while fostering tick resistance to these agents due to improper and intensive application.

View Article and Find Full Text PDF

Human epidermal growth factor receptor 2 (HER2) is a critical biomarker and therapeutic target in gastric/gastroesophageal junction (G/GEJ) cancers, despite the initial success of HER2-targeted therapies, such as trastuzumab, resistance to these drugs has emerged as a major impediment to effective long-term treatment. This review examines the mechanisms of drug resistance in HER2-positive G/GEJ cancer, the primary mechanisms of resistance explored include alterations in the HER2 receptor itself, such as mutations and changes in expression levels, as well as downstream signaling pathways, and interactions with the tumor microenvironment (TME). Furthermore, the review discusses the Novel therapeutic approaches, including the use of antibody-drug conjugates (ADCs) and combination therapies are assessed for their potential to enhance outcomes.

View Article and Find Full Text PDF

Objectives: Safety and immunogenicity assessment of updated monovalent and bivalent SARS-CoV-2 vaccines in adolescents.

Methods: This phase 3, double-blinded study randomised 12-<18-year-old participants, who received ≥2 prior doses of an approved/authorised mRNA-based COVID-19 vaccine, 1:1 to receive NVX-CoV2601 (XBB.1.

View Article and Find Full Text PDF

Unlabelled: Human norovirus (HuNoV) is a leading cause of gastroenteritis worldwide and is associated with significant morbidity, mortality, and economic impact. There are currently no licensed antiviral drugs for the treatment of HuNoV-associated gastroenteritis. The HuNoV protease plays a critical role in the initiation of virus replication by cleaving the polyprotein.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!